Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT04879316
What this trial is testing

Energy for Lymphocytes

Who this might be right for
Non-small Cell Lung CancerProgression, Disease
Hôpital Cochin 144
Early research (Phase 1)Active Not RecruitingNCT04387084
What this trial is testing

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Who this might be right for
Advanced Malignant Skin NeoplasmMetastatic Malignant Skin Neoplasm
University of Southern California 10
Testing effectiveness (Phase 2)Study completedNCT03631784
What this trial is testing

A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)

Who this might be right for
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC 216
Testing effectiveness (Phase 2)Ended earlyNCT03050814
What this trial is testing

Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004

Who this might be right for
Colorectal TumorsColorectal NeoplasmsColorectal Carcinoma+2 more
National Cancer Institute (NCI) 30
Not applicableStudy completedNCT05332821
What this trial is testing

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

Who this might be right for
Hepatocellular Carcinoma
Zhongda Hospital 1,244
Not applicableLooking for participantsNCT05713994
What this trial is testing

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD 300
Not applicableUnknownNCT03816657
What this trial is testing

The Predictive Role of Programmed Death Ligand 1 (PD-L1) and Neutrophil to Lymphocyte Ratio (NLR) in Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
To Define an Easy and Feasible Panel Which May be Routinely Applied to Select Patients for Immunotherapy Avoiding More Complex and Expensive Methods
Fondazione Ricerca Traslazionale 93
Large-scale testing (Phase 3)Study completedNCT01866319
What this trial is testing

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006)

Who this might be right for
Melanoma
Merck Sharp & Dohme LLC 834
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06925048
What this trial is testing

SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment naïve or Acquired Resistant to Immunology NSCLC

Who this might be right for
Non-Small Cell Lung CancerJAK InhibitorImmunology
Chunxia Su 86
Early research (Phase 1)Study completedNCT04242238
What this trial is testing

Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas

Who this might be right for
SarcomaAdvanced SarcomaHigh Grade Sarcoma+4 more
Memorial Sloan Kettering Cancer Center 32
Not applicableUnknownNCT05717738
What this trial is testing

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Who this might be right for
Hepatocellular Carcinoma Non-resectable
Tongji Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT06429696
What this trial is testing

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer Extensive Stage
Nanfang Hospital, Southern Medical University 40
Very early researchLooking for participantsNCT04684459
What this trial is testing

Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors

Who this might be right for
Peritoneal Carcinoma MetastaticPleural Effusion, MalignantHER2 Positive Malignancies
Sichuan University 18
Large-scale testing (Phase 3)Not Yet RecruitingNCT07385079
What this trial is testing

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Who this might be right for
Nasopharyngeal Cancinoma (NPC)Nasopharyngeal Cancer
Sun Yat-sen University 412
Large-scale testing (Phase 3)Looking for participantsNCT06170788
What this trial is testing

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC 614
Testing effectiveness (Phase 2)Ended earlyNCT03317496
What this trial is testing

Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies

Who this might be right for
Non-small Cell Lung CancerUrothelial Cancer
Pfizer 67
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07450183
What this trial is testing

Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1

Who this might be right for
Lung Cancer (NSCLC)
Henry Ford Health System 33
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Testing effectiveness (Phase 2)UnknownNCT04739670
What this trial is testing

Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer

Who this might be right for
Metastatic Triple Negative Breast Cancer
Peter MacCallum Cancer Centre, Australia 31
Large-scale testing (Phase 3)Study completedNCT02008227
What this trial is testing

Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy

Who this might be right for
Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche 1,225
Next Page